Jason Sheasby is a partner at Irell & Manella LLP in Los Angeles. He is known for trying and winning complex intellectual property cases involving semiconductors, pharmaceuticals, telecommunications, and emerging technologies.
The verdict in the Netlist case came swiftly. Jurors in the Eastern District of Texas found that Micron had willfully infringed two patents related to computer memory technology and awarded $445 million in damages. It was May 23, 2024. For Jason Sheasby, it was another courtroom win in a stretch of trials that had begun to blur together.
In less than two years, he took more than nine highly complex, high-stakes cases to trial and won each. The matters involved rival semiconductor manufacturers, telecommunications standards, pharmaceutical royalties, and medical devices. The pace alone would test most litigators. The scale of the verdicts, often in the hundreds of millions, placed him in a narrow band of lawyers who regularly argue at the outer edge of commercial litigation.
Sheasby, a partner at Irell & Manella LLP in Los Angeles, focuses on intellectual property disputes. His practice moves easily between patents, trade secrets, antitrust claims, regulatory compliance, and internal investigations. The industries change. The stakes do not.
The Trial as Center of Gravity
Over the past several years, the trial has become the organizing principle of Sheasby’s work.
In January 2024, he served as co-lead counsel for G+ Communications in a patent infringement trial in the Eastern District of Texas. The jury found infringement of two patents and awarded $67.5 million in damages, rejecting Samsung’s counterclaim that G+ had breached its obligation of good faith negotiation. When the damages portion of the verdict was vacated, a retrial followed in April. The jury awarded $142 million, the full amount requested.
Less than three weeks later, he was back in court. On May 17, 2024, in the Central District of California, a jury returned a complete verdict for Netlist in a contract action against Samsung. The dispute centered on whether Samsung had materially breached a license agreement requiring it to supply critical NAND and DRAM products. The jury unanimously sided with Netlist. The outcome preserved a prior patent infringement verdict exceeding $300 million that Sheasby had secured in 2023.
Six days after that, the Micron verdict landed in Texas.
By November 22, 2024, he secured yet another trial victory for Netlist against Samsung. Jurors found infringement on all three asserted patents, willful infringement, and $118 million in damages. It marked the third trial win for Netlist that year.
The repetition is striking. So is the scale.
In October 2023, as co-lead counsel, Sheasby scored a $240 million verdict for StreamScale in a patent infringement suit against Cloudera involving cloud data storage technology. In January 2023, he secured a $59.5 million verdict for DePuy Synthes, a Johnson & Johnson company, in a patent trial over medical devices for canine knee injuries. Jurors found willful infringement and awarded the full amount requested.
There were also defense victories. In October 2023, he achieved a complete summary judgment win in a contract dispute involving T-Mobile and KAIFI, persuading the court that the plaintiff’s claims could not proceed. And in a week-long arbitration over a royalty agreement relating to emtricitabine, an antiviral medicine for HIV treatment, he represented Gilead and secured a complete defense victory, including attorneys’ fees. A Georgia court confirmed the award in August 2024.
Across these cases, the through line is not the technology itself, but the courtroom.
Mastering the Technical Frontier
Sheasby’s docket reads like a survey course in modern industry. Semiconductor packaging. 5G telecommunications standards. Memory module decoders. Antibody therapies. Bulk FinFET technology. Mobile remote deposit capture. Genomics.
Described in Chambers USA as having a remarkable ability to devise creative solutions, he has litigated patents involving medicinal chemistry, genomics, polymer chemistry, optics, computer microarchitecture, and semiconductor packaging. In a single year earlier in his career, he successfully reversed a $2.5 billion patent verdict in a medicinal chemistry case and obtained a $400 million jury verdict against a semiconductor manufacturer.
He has prevailed in multiple jury trials totaling more than $800 million in verdicts within a twelve-month period. He secured a $500 million verdict against Apple during the first patent jury trial of the COVID-19 pandemic, with jurors finding willful infringement and awarding an ongoing royalty. He obtained more than $300 million in awards for USAA in patent trials against Wells Fargo. He achieved a perfect 29-0 record in Patent Trial and Appeal Board proceedings on behalf of a patent owner in the USB charging sector.
The cases vary, but the pattern is consistent. Complex science distilled into narrative. Technical disputes translated for juries. Administrative challenges navigated alongside district court litigation.
He has also handled internal investigations involving regulatory compliance with the U.S. Department of Health and Human Services, including anti-kickback inquiries and trade secret issues. The work extends beyond trial theatrics into the dense procedural thicket that surrounds high-stakes litigation.
From San Bernardino to Harvard
Sheasby grew up in San Bernardino County, California. He earned a B.A. in Philosophy from Pomona College in 1996, graduating summa cum laude and elected to Phi Beta Kappa. He then attended Harvard Law School, receiving his J.D. in 1999, cum laude.
At Harvard, he served as a research assistant to Professor Arthur Miller and helped revise Federal Practice & Procedure, a leading treatise on civil procedure. The work placed him close to the architecture of litigation itself. The procedural rules that govern complex federal cases would later become daily tools.
He joined Irell & Manella and has spent more than twenty-five years with the firm. Today, he serves as a key partner in its litigation group. His name appears repeatedly in legal rankings and awards: Litigator of the Year by The American Lawyer in 2024, Patent Star by Managing IP in 2025, Litigator of the Year by Managing IP Americas Awards in 2025, and a finalist for IP Lawyer of the Year by The Recorder in 2024. He has been selected to the Lawdragon 500 Leading Global IP Lawyers list and repeatedly named a Trials MVP by Law360.
The honors reflect output rather than style. A steady cadence of verdicts, appeals, retrials, and post-judgment reversals.
Beyond the Courtroom
Litigation defines the public record, but Sheasby’s professional footprint extends elsewhere.
He is a co-founder of TORL Biotherapeutics, a biopharmaceutical company developing antibody therapies for high-unmet-need cancers, including ovarian and pancreatic cancer. The company’s first two drugs are in human clinical trials. His involvement follows years of representing research universities and biotechnology clients, working at the intersection of patent law and medical innovation.
He also serves on the board of trustees for Pomona College, returning to the institution where he studied philosophy as an undergraduate.
The interests align with his practice. Protecting intellectual property in court on one front. Supporting the commercialization of biomedical research on another.
The Weight of Scale
The sums attached to Sheasby’s cases are difficult to ignore. $445 million. $142 million. $118 million. $240 million. $59.5 million. Earlier in his career, a $2.5 billion verdict reversed. In other years, more than $600 million in plaintiffs’ verdicts within ten months.
Such figures can distort perception. They suggest spectacle. Yet trial practice at this level is as much about endurance as it is about drama. In 2024, he tried multiple cases within weeks of each other. In recent years, he has tried eleven cases with verdicts exceeding $100 million, more than any other patent litigator in the nation over that period.
The rhythm is relentless. Pretrial motions. Expert depositions. Jury selection. Closing arguments. Post-trial briefing. Appeals. Then the next case.
In technology sectors where innovation cycles are measured in months, not years, the courtroom has become an arena where competitive advantage is fought as fiercely as in research labs. Patent portfolios shape market power. License agreements dictate supply chains. Antitrust claims shadow licensing negotiations.
Lawyers who can navigate both the technical and the theatrical dimensions of this terrain are rare.
Why Jason Sheasby Matters Now
The modern economy runs on code, semiconductors, biomedical breakthroughs, and global standards. Disputes over who owns, licenses, or infringes that intellectual property are no longer peripheral. They are central to how industries compete.
Jason Sheasby’s recent record reflects this reality. His cases have involved memory modules that enable data-intensive servers, 5G telecommunications standards, cloud data storage systems, and life-saving antiviral medications. The verdicts have shaped not only corporate balance sheets, but the contours of technological competition.
He operates in a space where the details are dense and the consequences are vast. The work requires fluency in science and procedure, comfort before juries, and stamina across back-to-back trials.
In a legal landscape often dominated by settlements and quiet resolutions, Sheasby’s career has been defined by verdicts. The courtroom remains his proving ground.
And in an era when intellectual property disputes are proxies for broader economic battles, the lawyer who can repeatedly carry complex technology cases across the finish line occupies a consequential place in the story of modern industry.
